You are here

  • Home
  • Online First
  • Nicotine replacement therapy increases quit attempts among unmotivated smokers when added to encouragement to practice quitting

Article Text

Article menu

other Versions

Download PDFPDF
Therapeutics
Randomised controlled trial
Nicotine replacement therapy increases quit attempts among unmotivated smokers when added to encouragement to practice quitting
  1. Saul Shiffman
  1. Correspondence to Saul Shiffman
    Smoking Research Group, University of Pittsburgh, 130 Desoto St # A526, Pittsburgh, PA 15213, USA; shiffman{at}pitt.edu

https://doi.org/10.1136/ebmed-2012-100776

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Carpenter MJ, Hughes JR, Gray KM, et al. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. Arch Intern Med 2011;171:1901–7.OpenUrlCrossRefPubMedWeb of Science

    Context

    Smoking cessation is an urgent public health priority. Clinical interventions typically focus on improving outcomes for smokers trying to quit; encouraging quit attempts is often left to public education. In particular, nicotine replacement therapy (NRT) is typically only given to smokers actively quitting. This study by Carpenter et al tested whether encouraging smokers who were not ready to quit by using NRT in a practice quit attempt (PQA) increases quit attempts.

    Methods

    Smokers (n=849) not interested in quitting within 30 days received three phone calls over 6 weeks, encouraging PQAs lasting for a few hours or a few days; the final call encouraged smokers to make a real quit attempt. Half the participants were randomised to additionally …

    View Full Text

    Footnotes

    • Competing interests SS consults with GlaxoSmithKline exclusively on matters related to smoking cessation, and is a partner in a company trying to develop novel nicotine therapies.